Navigation Links
CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
Date:4/10/2008

at CV Therapeutics has received approval for in just over two years," stated Louis G. Lange, M.D., Ph.D., chairman and chief executive officer of CV Therapeutics. "We are very excited to have Astellas -- the clear market leader in pharmacologic stress for MPI -- commercializing Lexiscan."

"We are extremely pleased that the FDA has approved Lexiscan, an exciting new option for diagnosing coronary artery disease in patients who cannot undergo an exercise stress test," said Yoshihiko Hatanaka, president and chief executive officer of Astellas Pharma US, Inc. "We are preparing to launch Lexiscan soon after this approval in order to provide clinicians with this important new option for patients who need pharmacologic stress agents for MPI studies."

Lexiscan Clinical Trials

In two identically designed Phase III clinical trials, Lexiscan met primary endpoints for scan agreement rates by showing with 95 percent confidence that MPI studies conducted with Lexiscan were similar to MPI studies conducted with Adenoscan(R) (adenosine injection).

Lexiscan was generally well-tolerated in both Phase III studies. The most common adverse events reported in patients who received Lexiscan were shortness of breath, headache, flushing, chest discomfort, dizziness and nausea.

About Lexiscan

Lexiscan is an A2A adenosine receptor agonist approved for use as a pharmacologic stress agent in radionuclide MPI studies in patients unable to undergo adequate exercise stress. Lexiscan was designed to produce coronary vasodilation and increase coronary blood flow by activation of the A2A adenosine receptor. Lexiscan is administered as a rapid bolus (approximately 10 seconds) with no dose adjustment required for body weight. Lexiscan should not be administered to patients with second- or third-degree AV block or sinus node dysfunction who do not have a functioning artificial pacemaker. Adenosine receptor agonists, including Lexiscan, induce arterial vasodilati
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Stemline Therapeutics Raises $12.5 Million
2. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
3. Amsterdam Molecular Therapeutics Part of Next Biotech Index
4. Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium
5. Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer
6. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
7. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
8. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
9. Mercury Therapeutics Patents Filed
10. Cell Therapeutics, Inc. Announces Filing of Form 10-K
11. Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/22/2014)... DIEGO and HONG KONG ... innovative rare disease therapeutics enterprise, announced today that rare ... the company as vice president, research. Dr. McKew brings ... including key leadership positions at the National Institutes of ... its acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts ...
(Date:10/20/2014)... 2014 Convey Computer , the ... from Iowa State University won first place in the ... Convey HC-2ex, the team’s solution achieved the highest overall ... the second place finisher. , Experts from all segments ... month long challenge, using a variety of design tools, ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... INCLINE VILLAGE, Nev., Sept. 8 PDL BioPharma, ... guidance for the third quarter ended September 30, 2009 of ... third quarter of 2008. Royalty revenues are based on second ... for Synagis(R), which is marketed by MedImmune. When compared with ...
... NOVATO, Calif., Sept. 8 BioMarin Pharmaceutical Inc. (Nasdaq: ... will present a company update at the Morgan Stanley Healthcare Conference in ... , , Interested parties may access a ... the BioMarin website, www.BMRN.com . A replay of ...
... 8 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) announced ... failure gout will be presented at the 2009 ACR/ARHP Annual Scientific ... posters will be presented during the "Treatment and Outcome" session on ... , Chronic Use of Pegloticase: Safety ...
Cached Biology Technology:PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million 2PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million 3BioMarin to Present at the Morgan Stanley Healthcare Conference 2Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 2Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 3Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 4
(Date:10/16/2014)... 2014) – Post-menopausal women experienced improvements in vaginal ... or genital bleeding, after 12 weeks of daily ... soy germ-based nutritional supplement previously shown to help ... peer-reviewed pilot study reported in a poster at ... meeting. , "These data documented improved vaginal ...
(Date:10/15/2014)... the pandemic risk from strains of influenza virus increases ... ourselves to become complacent that the most substantial threats ... , Influenza pandemics arise when a new virus strain ... immunity – spreads in the human population. There have ... the worst of which – the 1918 Spanish Flu ...
(Date:10/15/2014)... spreading rapidly and to an unexpected extent. The outbreak ... and the virus shows a new disease dynamic in ... this reason, the German National Academy of Sciences Leopoldina, ... and the Union of the German Academies of Sciences ... epidemic today. , In the statement the academies call ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... Luxembourg Centre for Systems Biomedicine (LCSB) of the University ... from which differentiated cells for instance skin cells ... cell types such as nerve cells, for example. ... computer-based instructions for reprogramming cells are of huge significance ...
... rats have long since been a standard animal model for ... years on average and high incidence of cancer. Naked mole ... African subterranean rodent has a maximum lifespan exceeding 30 years ... not a single incident of cancer has been detected makes ...
... central nervous system is injured, oligodendrocyte precursor cells (OPC) ... on demyelinated axons. Scientists at the Institute of Molecular ... now discovered that a distinct protein regulates the direction ... protein NG2, which is expressed at the surface of ...
Cached Biology News:Computational biology: Cells reprogrammed on the computer 2The naked mole-rat's secret to staying cancer free 2Scientists at Mainz University decode mechanisms of cell orientation in the brain 2
Sheep polyclonal to Quinolone ( Abpromise for all tested applications). Antigen: Norfloxacin(N)conjugated to BSA...
...
...
... the 9, 10, 12, and 13 positions. It ... for the quantification of 9(S)-HODE by GC- or ... of linoleic acid in both plants and animals. ... an esterified component of membrane phospholipids and in ...
Biology Products: